Rubius Therapeutics
620 Memorial Drive
Suite 100W
Cambridge
Massachusetts
02139
United States
Tel: 617-218-1606
Website: http://www.rubiustx.com/
76 articles with Rubius Therapeutics
-
Rubius Therapeutics to Present at Jefferies Virtual 2020 Healthcare Conference
5/26/2020
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced that Pablo J. Cagnoni, M.D., chief executive officer, will participate in a fireside chat at the Jefferies Virtual 2020 Healthcare Conference on Tuesday, June 2, 2020, at 1:00 p.m. ET.
-
Rubius Therapeutics to Present Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers at the American Association of Cancer Research Annual Meeting
5/15/2020
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the Company plans to present preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of human papillomavirus (HPV) 16-positive cancers, during the American Association f
-
Rubius Therapeutics Highlights Preclinical Data for RTX-321, a Red Cell Therapeutic™ Oncology Product Candidate for HPV-Positive Cancers, at the American Society of Gene & Cell Therapy 23rd Annual Meeting
5/12/2020
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today presented preclinical data supporting its lead artificial antigen-presenting cell (aAPC) program, RTX-321, for the potential treatment of HPV 16-positive tumors at the American Society of Gene and Cell Therapy 23rd Annual Meeting. The meeting is being he
-
Rubius Therapeutics Reports First Quarter 2020 Financial Results and Provides Operational Update
5/11/2020
Completed Strategic Reprioritization of Pipeline to Focus on Oncology and Autoimmunity Dosed First Patient in Phase 1/2 Clinical Trial of RTX-240 for Advanced Solid Tumors Successfully Produced cGMP Clinical Supply of RTX-240 from Fully Owned Manufacturing Facility Strong Cash Position CAMBRIDGE, Mass., May 11, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an ent
-
Rubius Therapeutics Announces Dosing of First Patient in Phase 1/2 Trial of RTX-240, an Allogeneic Cellular Therapy, for the Treatment of Solid Tumors
5/7/2020
Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the first patient has been dosed in its Phase 1/2 clinical trial of RTX-240 for the treatment of patients with relapsed/refractory or locally advanced solid tumors. RTX-240 is an allogeneic, off-the-shelf Red Cell Therapeutic™ that is eng
-
Rubius Therapeutics to Announce First Quarter 2020 Financial Results
5/4/2020
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced plans to report first quarter 2020 financial results on Monday, May 11, 2020, before market open.
-
Rubius Therapeutics Announces Preclinical Data from Red Cell Therapeutic Oncology Programs to be Presented at the ASGCT 23rd Annual Meeting
4/29/2020
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the company will present preclinical data from its oncology pipeline of Red Cell Therapeutics™ (RCTs) at the American Society of Gene and Cell Therapy (ASGCT) 23 rd Annual Meeting. The meeting is being held virtually from May 12 – 15, 2
-
Rubius Therapeutics is minimizing its focus on its rare disease pipeline and taking greater aim at developing treatments for cancer and autoimmune diseases.
-
Rubius Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Announces Strategic Focus on Oncology and Autoimmunity
3/12/2020
Rubius Therapeutics, Inc. today reported fourth quarter and full year 2019 financial results.
-
Rubius Therapeutics to Report Fourth Quarter and Full-Year 2019 Financial Results and Host Webcast
3/3/2020
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that it will report fourth quarter and full-year 2019 financial results and provide a business update on Thursday, March 12, 2020.
-
Clinical Catch-Up: January 27-31
2/3/2020
It was another busy week for clinical trial updates. Here’s a look. -
Rubius Therapeutics Announces First Patient Dosed in Phase 1b Trial of RTX-134 for the Treatment of Patients with Phenylketonuria
1/30/2020
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that the first patient has been dosed in its Phase 1b trial of RTX-134, an allogeneic, off-the-shelf cellular therapy for the potential treatment of patients with phenylketonuria (PKU).
-
Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference
1/13/2020
RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration
-
Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer
1/8/2020
Rubius Therapeutics, Inc. announced the appointment of Laurence Turka, M.D., as its first chief scientific officer, effective January 21, 2020.
-
Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference
1/2/2020
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced today that Pablo J. Cagnoni, M.D., chief executive officer, will present at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco,
-
Rubius Therapeutics Appoints Christina Coughlin, M.D., Ph.D., as Chief Medical Officer
12/23/2019
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Christina Coughlin, M.D., Ph.D., as the Company’s chief medical officer, effective January 6, 2020.
-
Rubius Therapeutics Appoints Anne Prener, M.D., Ph.D., to its Board of Directors
12/18/2019
Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced the appointment of Anne Prener, M.D., Ph.D., to its board of directors
-
Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress
11/14/2019
Rubius Therapeutics, Inc. reported third quarter 2019 financial results and provided an overview of operational progress.
-
Rubius Therapeutics to Participate in Jefferies London Healthcare Conference
11/12/2019
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced that Pablo J. Cagnoni, M.D., chief executive officer, will present at Jefferies London Healthcare Conference Wednesday, November 20, 2019, at 10:00 a.m. GMT / 5:00 a.m. EST.
-
Rubius Therapeutics Appoints Maiken Keson-Brookes as Chief Legal Officer and Corporate Secretary
11/12/2019
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, announced the appointment of Maiken Keson-Brookes as chief legal officer and corporate secretary.